甲状腺髓样癌的影像学进展
The Imaging Progress of Medullary Thyroid Carcinoma
DOI: 10.12677/ACM.2021.1110656, PDF,   
作者: 方献柳, 左 阳*：广西医科大学附属肿瘤医院影像中心，广西 南宁
关键词: 甲状腺髓样癌；降钙素；影像学检查；Medullary Thyroid Carcinoma； Calcitonin； Imaging Examination
摘要: 甲状腺癌是较常见的内分泌系统肿瘤之一，甲状腺髓样癌(medullary carcinoma of the thyroid, MTC)是来源于滤泡旁细胞(C细胞)的肿瘤，占据甲状腺癌的1%~5%。MTC与其他类型的甲状腺癌相比，在生物学行为以及预后方面存在明显差异，在临床上较为罕见，但其恶性程度高，且对放化疗不敏感，因而早期确诊MTC具有非常重要的临床意义。MTC的术前诊断以及术后肿瘤复发诊断主要依靠影像学检查，特本文就现有影像学检查对MTC的诊断及其研究进展进行综述。
Abstract: Thyroid cancer is one of the most common endocrine system tumors. Medullary carcinoma of the thyroid (MTC) is a tumor derived from parafollicular cells (C cells), which accounts for 1% to 5% of thyroid cancers. Compared with other types of thyroid cancer, MT has obvious differences in biological behavior and prognosis. It is relatively rare in clinical practice, but its malignant degree is high, and it is not sensitive to radiotherapy and chemotherapy. Therefore, early diagnosis of MTC has very important clinical significance. The preoperative diagnosis of MTC and the diagnosis of postoperative tumor recurrence mainly rely on imaging examinations. This article reviews the existing imaging examinations for the diagnosis of MTC and its research progress.
文章引用：方献柳, 左阳. 甲状腺髓样癌的影像学进展[J]. 临床医学进展, 2021, 11(10): 4480-4484. https://doi.org/10.12677/ACM.2021.1110656

参考文献

[1] Nilsson, M. and Williams, D. (2016) On the Origin of Cells and Derivation of Thyroid Cancer: C Cell Story Revisited. European Thyroid Journal, 5, 79-93. [Google Scholar] [CrossRef] [PubMed]
[2] Roy, M., Chen, H. and Sippel, R.S. (2013) Current Understanding and Management of Medullary Thyroid Cancer. Oncologist, 18, 1093-1100. [Google Scholar] [CrossRef] [PubMed]
[3] Roman, S., Lin, R. and Sosa, J.A. (2006) Prognosis of Medullary Thyroid Carcinoma: Demographic, Clinical, and Pathologic Predictors of Survival in 1252 Cases. Cancer, 107, 2134-2142. [Google Scholar] [CrossRef] [PubMed]
[4] Treglia, G., Rufni, V., Salvatori, M., Giordano, A. and Giovanella, L. (2012) PET Imaging in Recurrent Medullary Thyroid Carcinoma. International Journal of Molecular Imaging, 2012, Article ID: 324686. [Google Scholar] [CrossRef] [PubMed]
[5] Trimboli, P., Guidobaldi, L., Bongiovanni, M., Crescenzi, A., Alevizaki, M. and Giovanella, L. (2016) Use of Fine-Needle Aspirate Calcitonin to Detect Medullary Thyroid Carcinoma: A Systematic Review. Diagnostic Cytopathology, 44, 45-51. [Google Scholar] [CrossRef] [PubMed]
[6] O’Connor, J.P.B., Rose, C.J., Jackson, A., et al. (2011) DCE-MRI Biomarkers of Tumour Heterogeneity Predict CRC Liver Metastasis Shrinkage Following Bevacizumab and FOLFOX-6. British Journal of Cancer, 105, 139-145. [Google Scholar] [CrossRef] [PubMed]
[7] Goo, H.W. (2015) Whole-Body MRI in Children: Current Imaging Techniques and Clinical Applications. Korean Journal of Radiology, 16, 973-985. [Google Scholar] [CrossRef] [PubMed]
[8] Van Cutsem, E., Verheul, H., Flamen, P., et al. (2016) Imaging in Colorectal Cancer: Progress and Challenges for the Clinicians. Cancers, 8, 81. [Google Scholar] [CrossRef] [PubMed]
[9] Taouli, B., Beer, A.J., Chenevert, T., et al. (2016) Diffusion-Weighted Imaging outside the Brain: Consensus Statement from an ISMRM-Sponsored Workshop. Journal of Magnetic Resonance Imaging, 44, 521-540. [Google Scholar] [CrossRef] [PubMed]
[10] Padhani, A.R., Koh, D.-M. and Collins, D.J. (2011) Whole-Body Diffusion-Weighted MR Imaging in Cancer: Current Status and Research Directions. Radiology, 261, 700-718. [Google Scholar] [CrossRef] [PubMed]
[11] Sung, Y.S., Park, B., Choi, Y., et al. (2016) Dynamic Contrast-Enhanced MRI for Oncology Drug Development. Journal of Magnetic Resonance Imaging, 44, 251-264. [Google Scholar] [CrossRef] [PubMed]
[12] Sherman, S.I. (2011) Targeted Therapies for Thyroid Tumors. Modern Pathology, 24, S44-S52. [Google Scholar] [CrossRef] [PubMed]
[13] Lam, E.T., Ringel, M.D., Kloos, R.T., et al. (2010) Phase II Clinical Trial of Sorafenib in Metastatic Medullary Thyroid Cancer. Journal of Clinical Oncology, 28, 2323-2330. [Google Scholar] [CrossRef] 
[14] Riola-Parada, C., Garcıa-Canamaque, L., Perez-Duenas, V., Garcerant-Tafur, M. and Carreras-Delgado, J. (2016) Simultaneous PET/MRI vs PET/CT in Oncology. A Systematic Review. Revista Espanola de Medicina Nuclear e Imagen Molecular, 35, 306-312. [Google Scholar] [CrossRef] 
[15] Wells Jr., S.A., Asa, S.L., Dralle, H., et al. (2015) Revised American Thyroid Association Guidelines for the Management of Medullary Thyroid Carcinoma. Thyroid, 25, 567-610. [Google Scholar] [CrossRef] [PubMed]
[16] Riddle, N.D. and Bui, M.M. (2013) Fibrous Dysplasia. Archives of Pathology & Laboratory Medicine, 137, 134-138. [Google Scholar] [CrossRef] 
[17] Treglia, G., Villani, M.F., Giordano, A. and Rufni, V. (2012) Detection Rate of Recurrent Medullary Thyroid Carcinoma Using Fuorine 18 Fluorodeoxyglucose Positron Emission Tomography: A Meta-Analysis. Endocrine Journal, 42, 535-545. [Google Scholar] [CrossRef] [PubMed]
[18] Treglia, G., Cocciolillo, F., Di Nardo, F., et al. (2012) Detection Rate of Recurrent Medullary Thyroid Carcinoma Using Fuorine-18 Dihydroxyphenylalanine Positron Emission Tomography: A Metaanalysis. Academic Radiology, 19, 1290-1299. [Google Scholar] [CrossRef] [PubMed]
[19] Sesti, A., Mayerhoefer, M., Weber, M., et al. (2014) Relevance of Calcitonin Cutoff in the Follow-Up of Medullary Thyroid Carcinoma for Conventional Imaging and 18-Fuorine-Fuorodihydroxyphenylalanine PET. Anticancer Research, 34, 6647-6654.
[20] Romero-Lluch, A.R., Cuenca-Cuenca, J.I., Guerrero-Vazquez, R., et al. (2017) Diagnostic Utility of PET/CT with 18F-DOPA and 18F-FDG in Persistent or Recurrent Medullary Thyroid Carcinoma: The Importance of Calcitonin and Carcinoembryonic Antigen Cutoff. European Journal of Nuclear Medicine and Molecular Imaging, 44, 2004-2013. [Google Scholar] [CrossRef] [PubMed]

为你推荐